A Phase 2 interventional study of IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen) in Lymphoma, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 42 sites in 2 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-31.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing busulfan in Lymphoma — 2 open to participants now, 6 under way, none of them phase 3. Busulfan · Lymphoma.
Among the 64 studies testing busulfan in Lymphoma, this one is the 5th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2010, is one of 41 in phase 2, and was the 41st registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →2 of the 64 studies testing busulfan in Lymphoma are open now, in 1 country. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages up to 26
National Cancer Institute (NCI) · Sites in United States
Ages 4–70
By country, each count listing its studies:
Busulfan: first FDA approval 1954 (MYLERAN), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 51 · Phase 3 1 · Phase 4 1
First in 1992; this study’s year is marked. 6 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 207 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 47 across the 63 interventional studies. Of the 53 that completed or were terminated, 36 (68%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 64 have an industry lead sponsor. The 10 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
Otsuka Holdings Co., Ltd. has 5 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
1 of the studies testing busulfan in Lymphoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
Add it to your calendar (.ics) → With an account.
Among the 64 studies testing busulfan in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study for the outcome and safety of individualized busulfan dosing with cyclophosphamide and etoposide for patients preparing for a stem cell transplant to treat Non-Hodgkin or Hodgkin's Lymphoma.
Evaluation of progression-free survival, transplant related mortality, overall survival, and overall response rate, in subjects with NHL and HL receiving an IV busulfan-based conditioning regimen with PK-guided IV busulfan dosing, followed by autologous HSCT as well as comparison to those receiving carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning regimen (and its variants) obtained from registry data in the Center for International Blood and Marrow Transplant Research (CIBMTR) Assessment of the safety profile of a BuCyE conditioning regimen with PK-directed dosing of IV busulfan will also be completed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects with NHL to be included:
Subjects with HL to be included:
Exclusion Criteria:
Excluded will also be subjects with existing or active central nervous system lymphoma or related lymphoma, unacceptable organ function, or uncontrolled infections.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant
Drug: IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Drug pages: Busulfan · Cyclophosphamide · Etoposide
Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
Number of Progression Events in 2 Years.
The time of Progression-Free Survival (PFS) was defined as the time from transplantation to the occurrence of the event that was death or first recurrence of progressive disease.
Time frame: 2 years
Number of Death Events in 2 Years.
The time of overall survival was defined as the time from transplantation to death of all causes.
Time frame: 2 years
Number of Transplant-related Death Events Until Day 100.
Transplant-related mortality was defined as death due to any cause other than disease relapse/progression up until Day 100.
Time frame: Day 100
Overall Response Rate
The overall response status is complete response and not complete response (partial remission, primary refractory/primary induction failure, stable disease, progressive disease, and relapse) at Baseline and each of the scheduled follow-up time points.
Time frame: Baseline, Day 100, Month 6, 12, 24, Early termination and End of Trial (within 30 days of the trial termination)
A multicenter (43 trial sites in United States and Canada), single-arm, open-label, phase 2 exploratory trial to evaluate clinical outcomes following pharmacokinetic (PK)-directed intravenous (IV) busulfan therapy in 207 participants with Non-Hodgkin's and Hodgkin's lymphoma were evaluated.
| Milestone | Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's Lymphoma (> 65 Years) | Non-Hodgkin's Lymphoma (≤ 65 Years) | Non-Hodgkin's Lymphoma (> 65 Years) |
|---|---|---|---|---|
| Started | 65 | 1 | 123 | 18 |
| Completed | 22 | 0 | 67 | 7 |
| Not completed | 43 | 1 | 56 | 11 |
The time of Progression-Free Survival (PFS) was defined as the time from transplantation to the occurrence of the event that was death or first recurrence of progressive disease.
| Event | Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's Lymphoma (> 65 Years) | Non-Hodgkin's Lymphoma (≤ 65 Years) | Non-Hodgkin's Lymphoma (> 65 Years) |
|---|---|---|---|---|
| Number of Progression Events in 2 Years. | 41 | 1 | 46 | 8 |
The time of overall survival was defined as the time from transplantation to death of all causes.
| Deaths | Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's Lymphoma (> 65 Years) | Non-Hodgkin's Lymphoma (≤ 65 Years) | Non-Hodgkin's Lymphoma (> 65 Years) |
|---|---|---|---|---|
| Number of Death Events in 2 Years. | 13 | 1 | 28 | 6 |
Transplant-related mortality was defined as death due to any cause other than disease relapse/progression up until Day 100.
| Transplant-related death | Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's Lymphoma (> 65 Years) | Non-Hodgkin's Lymphoma (≤ 65 Years) | Non-Hodgkin's Lymphoma (> 65 Years) |
|---|---|---|---|---|
| Number of Transplant-related Death Events Until Day 100. | 1 | 1 | 5 | 3 |
The overall response status is complete response and not complete response (partial remission, primary refractory/primary induction failure, stable disease, progressive disease, and relapse) at Baseline and each of the scheduled follow-up time points.
| Participants | Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's Lymphoma (> 65 Years) | Non-Hodgkin's Lymphoma (≤ 65 Years) | Non-Hodgkin's Lymphoma (> 65 Years) |
|---|---|---|---|---|
| Baseline-Complete Response (N=65, 0, 121, 16) | 35 | 0 | 72 | 12 |
| Baseline-Not Complete Response (N=65, 1, 121, 16) | 30 | 1 | 49 | 4 |
| Day 100-Complete Response (N=57, 0, 114, 12) | 35 | 0 | 85 | 8 |
| Day 100-Not Complete Response (N=57, 0, 114, 12) | 22 | 0 | 29 | 4 |
| Month 6-Complete Response (N=45, 0, 98, 11) | 30 | 0 | 84 | 9 |
| Month 6-Not Complete Response (N=45, 0, 98, 11) | 15 | 0 | 14 | 2 |
| Month 12-Complete Response (N=32, 0, 88, 8) | 22 | 0 | 71 | 8 |
| Month 12-Not Complete Response (N=32, 0, 88, 0) | 10 | 0 | 17 | 0 |
| Month 24-Complete Response (N=13, 0, 28, 6) | 11 | 0 | 26 | 6 |
| Month 24-Not Complete Response (N=13, 0, 28, 0) | 2 | 0 | 2 | 0 |
| Early Term-Complete Response (N=40, 0, 41, 0) | 2 | 0 | 4 | 0 |
| Early Term-Not Complete Response (N=40, 0, 41, 5) | 38 | 0 | 37 | 5 |
| End of Trial-Complete Response (N=22, 0, 71, 9) | 20 | 0 | 65 | 8 |
| End of Trial-Not Complete Response(N=22, 0, 71, 9) | 2 | 0 | 6 | 1 |
Collected over Adverse events were reported during the entire trial period (from screening through Early Termination or End of Trial).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years or > 65 Years) | — | 90/207 (43.5%) | 190/207 (91.8%) |
| Event | Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years or > 65 Years) |
|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 9/207 |
| PyrexiaGeneral disorders | 9/207 |
| PneumoniaInfections and infestations | 9/207 |
| SepsisInfections and infestations | 8/207 |
| HypotensionVascular disorders | 7/207 |
| StomatitisGastrointestinal disorders | 6/207 |
| Renal failure acuteRenal and urinary disorders | 6/207 |
| Atrial fibrillationCardiac disorders | 5/207 |
| Septic shockInfections and infestations | 4/207 |
| DehydrationMetabolism and nutrition disorders | 4/207 |
| Event | Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years or > 65 Years) |
|---|---|
| DiarrhoeaGastrointestinal disorders | 179/207 |
| StomatitisGastrointestinal disorders | 170/207 |
| NauseaGastrointestinal disorders | 169/207 |
| VomitingGastrointestinal disorders | 132/207 |
| Febrile neutropeniaBlood and lymphatic system disorders | 129/207 |
| FatigueGeneral disorders | 104/207 |
| HypokalaemiaMetabolism and nutrition disorders | 100/207 |
| PyrexiaGeneral disorders | 94/207 |
| Decreased appetiteMetabolism and nutrition disorders | 94/207 |
| InsomniaPsychiatric disorders | 86/207 |
| Age, Continuous(Years) | Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's/Non-Hodgkin's Lymphoma (> 65 Years) | Total |
|---|---|---|---|
| Years | 46.5 ± 13.1 | 68.5 ± 2.3 | 48.5 ± 14 |
| Sex: Female, Male(Participants) | Hodgkin's/Non-Hodgkin's Lymphoma (≤ 65 Years) | Hodgkin's/Non-Hodgkin's Lymphoma (> 65 Years) | Total |
|---|---|---|---|
| Female | 66 | 2 | 68 |
| Male | 122 | 17 | 139 |
The record gives a start of Jan 2010, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Busulfan · Cyclophosphamide · Etoposide
Otsuka Pharmaceutical Development & Commercialization, Inc. →